Imugene (ASX:IMU) received clearance from the Cohort Review Committee to escalate the dose level in the intravenous combination segment of its phase one onCARlytics trial, targeting adult patients with advanced or metastatic solid tumors, according to a Thursday Australian bourse filing.
The trial seeks to evaluate the safety and efficacy of different routes of administration, intratumoral injection, and intravenous infusion of either onCARlytics, a CD19-expressing oncolytic virus, alone, or in combination with CD19-targeting bispecific monoclonal antibody blinatumomab, which is a cancer immunotherapy.
The IV combination arm will progress to a higher dose level after the completion of the safety observation period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.